Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

Inclusion Criteria

• •Participants must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma.
• •All participants must have measurable disease.
• •Participants must have at least one "target lesion" to be used to assess response on this protocol.
• •Participants must not be eligible for a higher priority GOG protocol, if one exists.
• •Participants who have received one prior regimen must have a GOG Performance Status of 0, 1, or 2. Participants who have received two prior regimens must have a GOG Performance Status of 0 or 1.
• •Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
• •Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to registration.
• •Participants must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.
• •Participants must NOT have received any non-cytotoxic therapy for management of recurrent or persistent disease.
• •Participants of child-bearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraception (for example, intrauterine device \[IUD\], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment.